Alpha CognitionACOG +4.94%31 Cash Ratio is 10.00 as of Mar. 2026, which is 156% above its 10-year median of 3.90. GuruFocus rates ACOG with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 1,385 Biotechnology companies, Alpha Cognition ranks better than 80.14% on this metric.
Alpha Cognition has a Cash Ratio of 10.00. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Alpha Cognition's Cash Ratio or its related term are showing as below:
ACOG'
s Cash Ratio Range Over the Past 10 Years
Min: 0.24 Med: 3.9 Max: 16.22
Current: 10
During the past 6 years, Alpha Cognition's highest Cash Ratio was 16.22. The lowest was 0.24. And the median was 3.90.
ACOG's Cash Ratio is ranked better than 80.14% of 1385
companies
in the Biotechnology industry
Industry Median: 2.95
vs ACOG: 10.00
Alpha Cognition (NAS:ACOG) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Alpha Cognition Cash Ratio Related Terms
Alpha Cognition Cash Ratio Historical Data
* Premium members only.
The historical data trend for Alpha Cognition's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alpha Cognition's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Cognition Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpha Cognition's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Alpha Cognition's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpha Cognition (ACOG) has a Cash Ratio of 10.00 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Alpha Cognition and its competitors. This is 156% above median its historical median of 3.90. Over the past decade, Alpha Cognition's Cash Ratio has ranged from 0.24 to 16.22. According to the industry distribution chart, Alpha Cognition ranks #275 out of 1385 companies in the Biotechnology industry, placing it in the top 19.9%.
Is Alpha Cognition's Cash Ratio too high?
Alpha Cognition's current Cash Ratio of 10.00 is 156% above median its 10-year median of 3.90. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 16.22. The Biotechnology industry median Cash Ratio is 2.95. Alpha Cognition's value of 10.00 is 239% above this industry median. Based on the distribution chart, Alpha Cognition ranks #275 out of 1385 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alpha Cognition has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Cognition's Cash Ratio compare to HURA and MENS?
According to the Biotechnology industry distribution chart, Alpha Cognition ranks #275 out of 1385 companies for Cash Ratio. This places Alpha Cognition in the top 20% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.95. Alpha Cognition's value of 10.00 is 239% above this benchmark. Historically, Alpha Cognition's own Cash Ratio has ranged from 0.24 to 16.22 over the past decade. While the company's 10-year median is 3.90 vs. the industry median of 2.95, Alpha Cognition has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.95, based on 1,385 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alpha Cognition's current Cash Ratio of 10.00 is 239% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Alpha Cognition and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpha Cognition's current Cash Ratio is 10.00, which is 156% above median its own 10-year median of 3.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Cognition stock overvalued right now?
Alpha Cognition (ACOG) has a current Cash Ratio of 10.00. The current Cash Ratio is 10.00, which is 156% above median its 10-year median of 3.90 and 239% above the Biotechnology industry median of 2.95. Alpha Cognition's overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Alpha Cognition (ACOG), the current Cash Ratio is 10.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
31GF Score
Get the complete analysis for ACOG
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACOG has been successfully added to your 
